Market research

ICVX Icosavax Inc

NASDAQ USD Healthcare

Latest close

— —

Loading market data…

Test a moving-average rule with historical data.

Market facts

Market cap: 769M
P/E ratio: Not available
Analyst target: 18.5
Dividend yield: Not available
Beta: 1.28

Loading price history…

Profile

Company facts

Exchange: NASDAQ
Currency: USD
Sector: Healthcare
Industry: Biotechnology
ISIN: US45114M1099
Market cap: 769M
P/E ratio: Not available
Analyst target: 18.5
Dividend yield: Not available
Beta: 1.28

About

About Icosavax Inc

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.

Visit company website

Reported results

Fundamentals

Open this section to load reported financial history.

Annual returns

No comments yet

Start a focused discussion about ICVX.

ICVX Icosavax Inc

Price & volume

Company facts

About Icosavax Inc

Fundamentals

Earnings

Cash flow

Profitability

Valuation

Performance

Annual returns

Investor discussion

No comments yet